摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3-硝基苯基)-氧代乙醛 | 6890-77-3

中文名称
(3-硝基苯基)-氧代乙醛
中文别名
——
英文名称
3-nitrophenylglyoxal
英文别名
2-(3-Nitrophenyl)-2-oxoacetaldehyde
(3-硝基苯基)-氧代乙醛化学式
CAS
6890-77-3
化学式
C8H5NO4
mdl
——
分子量
179.132
InChiKey
PPDGMLLCCLUIKZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    37-46 °C
  • 沸点:
    300.0±32.0 °C(Predicted)
  • 密度:
    1.376±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    80
  • 氢给体数:
    0
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2914400090

SDS

SDS:229f23c7035582293ae586af778cc469
查看

上下游信息

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS<br/>[FR] PYRROLOTRIAZINES EN TANT QU'INHIBITEURS D'ALK ET DE JAK2
    申请人:CEPHALON INC
    公开号:WO2010071885A1
    公开(公告)日:2010-06-24
    The present invention provides a compound of formula (I) or a salt form thereof, wherein Q1, Q2, Q3, and Q4 are as defined herein. The compound of formula (I) has ALK and/or JAK2 inhibitory activity, and may be used to treat proliferative disorders.
    本发明提供了一种式(I)的化合物或其盐形式,其中Q1、Q2、Q3和Q4如本文所定义。式(I)的化合物具有ALK和/或JAK2抑制活性,并可用于治疗增殖性疾病。
  • Modular Synthesis of Di- and Trisubstituted Imidazoles from Ketones and Aldehydes: A Route to Kinase Inhibitors
    作者:Ian de Toledo、Thiago A. Grigolo、James M. Bennett、Jonathan M. Elkins、Ronaldo A. Pilli
    DOI:10.1021/acs.joc.9b01844
    日期:2019.11.1
    A one-pot and modular approach to the synthesis of 2,4(5)-disubstituted imidazoles was developed based on ketone oxidation, employing catalytic HBr and DMSO, followed by imidazole condensation with aldehydes. This methodology afforded twenty-nine disubstituted NH-imidazoles (23%-85% yield). A three-step synthesis of 20 kinase inhibitors was achieved by employing this oxidation-condensation protocol
    基于酮氧化,采用催化HBr和DMSO,然后通过咪唑与醛的缩合反应,开发了一种单罐模块化方法,用于合成2,4(5)-二取代的咪唑。该方法提供了二十九个二取代的NH-咪唑(23%-85%的产率)。通过采用这种氧化-缩合方案,然后在咪唑环中进行溴化和Suzuki偶联,得到三取代的NH-咪唑(23%-69%,三步法),实现了三步合成20种激酶抑制剂的过程。该方法还用于合成已知抑制剂GSK3037619A。
  • Synthesis of 3-(3-aryl-pyrrolidin-1-yl)-5-aryl-1,2,4-triazines that have antibacterial activity and also inhibit inorganic pyrophosphatase
    作者:Wei Lv、Biplab Banerjee、Katrina L. Molland、Mohamed N. Seleem、Adil Ghafoor、Maha I. Hamed、Baojie Wan、Scott G. Franzblau、Andrew D. Mesecar、Mark Cushman
    DOI:10.1016/j.bmc.2013.11.011
    日期:2014.1
    Inorganic pyrophosphatases are potential targets for the development of novel antibacterial agents. A pyrophosphatase-coupled high-throughput screening assay intended to detect o-succinyl benzoic acid coenzyme A (OSB CoA) synthetase inhibitors led to the unexpected discovery of a new series of novel inorganic pyrophosphatase inhibitors. Lead optimization studies resulted in a series of 3-(3-aryl-p
    无机焦磷酸酶是开发新型抗菌剂的潜在靶点。旨在检测邻琥珀酰苯甲酸辅酶 A (OSB CoA) 合成酶抑制剂的焦磷酸酶偶联高通量筛选试验意外发现了一系列新的新型无机焦磷酸酶抑制剂。先导优化研究产生了一系列通过有效合成途径制备的 3-(3-aryl-pyrrolidin-1-yl)-5-aryl-1,2,4-triazine 衍生物。其中一种四环三嗪类似物22h显示出对多种耐药金黄色葡萄球菌菌株的有希望的抗生素活性,以及对结核分枝杆菌和炭疽芽孢杆菌,浓度对哺乳动物细胞无细胞毒性。
  • Quinoxaline Derivatives: Novel and Selective Butyrylcholinesterase Inhibitors
    作者:Aurang Zeb、Abdul Hameed、Latifullah Khan、Imran Khan、Kourosh Dalvandi、M. Choudhary、Fatima Basha
    DOI:10.2174/1573406410666140526145429
    日期:2014.5.26
    Alzheimer's disease (AD) is a progressive brain disorder which occurs due to lower levels of acetylcholine (ACh) neurotransmitters, and results in a gradual decline in memory and other cognitive processes. Acetycholinesterase (AChE) and butyrylcholinesterase (BChE) are considered to be primary regulators of the ACh levels in the brain. Evidence shows that AChE activity decreases in AD, while activity of BChE does not change or even elevate in advanced AD, which suggests a key involvement of BChE in ACh hydrolysis during AD symptoms. Therefore, inhibiting the activity of BChE may be an effective way to control AD associated disorders. In this regard, a series of quinoxaline derivatives 1-17 was synthesized and biologically evaluated against cholinesterases (AChE and BChE) and as well as against α- chymotrypsin and urease. The compounds 1-17 were found to be selective inhibitors for BChE, as no activity was found against other enzymes. Among the series, compounds 6 (IC50 = 7.7 ± 1.0 µM) and 7 (IC50 = 9.7 ± 0.9 µM) were found to be the most active inhibitors against BChE. Their IC50 values are comparable to the standard, galantamine (IC50 = 6.6 ± 0.38 µM). Their considerable BChE inhibitory activity makes them selective candidates for the development of BChE inhibitors. Structure-activity relationship (SAR) of this new class of selective BChE inhibitors has been discussed.
    阿尔茨海默病(AD)是一种渐进性脑部疾病,由于乙酰胆碱(ACh)神经递质水平降低而发生,导致记忆和其他认知过程逐渐衰退。乙酰胆碱酯酶(AChE)和丁酰胆碱酯酶(BChE)被认为是大脑中ACh水平的主要调节因子。证据显示,AD中AChE活性降低,而BChE活性不变甚至在前期的AD中升高,这表明在AD症状期间BChE在ACh水解中的关键作用。因此,抑制BChE活性可能是控制与AD相关障碍的有效方法。在这方面,合成了一系列喹喉化合物1-17,并对其对胆碱酯酶(AChE和BChE)以及α-胰凝乳蛋白酶和尿素酶的生物活性进行了评估。化合物1-17被发现是BChE的选择性抑制剂,因为它们对其他酶没有活性。在系列中,化合物6(IC50 = 7.7 ± 1.0 µM)和7(IC50 = 9.7 ± 0.9 µM)被发现是BChE的最有效抑制剂。它们的IC50值与标准药物加兰他敏(IC50 = 6.6 ± 0.38 µM)相当。它们显著的BChE抑制活性使它们成为开发BChE抑制剂的有选择性候选物。这一新类选择性BChE抑制剂的构效关系(SAR)已被讨论。
  • Enantioselective Cyanosilylation of α,α-Dialkoxy Ketones by Using Phosphine-Thiourea Dual-Reagent Catalysis
    作者:Qi-Wen Yu、Lu-Ping Wu、Tian-Chen Kang、Jin Xie、Feng Sha、Xin-Yan Wu
    DOI:10.1002/ejoc.201800459
    日期:2018.8.7
    An organophosphine‐catalyzed enantioselective cyanosilylation of carbonyl compounds has been disclosed for the first time. This process, the dual‐reagent catalysis serves as a powerful tool, affording the desired cyanohydrin trimethylsilyl ethers in excellent yields (up to 99 %) and good‐to‐excellent enantioselectivities (up to 94 % ee).
    首次公开了羰基化合物的有机膦催化对映选择性氰基硅烷化反应。这个过程,双试剂催化是一个强大的工具,以优异的收率(高达99%)和良好的对映体选择性(高达94%ee)提供了所需的氰醇三甲基甲硅烷基醚。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐